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Abstract  
COVID-19 may become a critical illness which is thought to be mediated by a cytokine 
storm syndrome. There is no effective anti-viral treatment to date and the mainstay of 
treatment is supportive. We treated 22 patients with severe COVID-19 with oral 
trimethoprim (TMP) or cotrimoxazole (CTX) in addition to standard antibiotic therapy 
(ST) and compared this with 22 patients with severe COVID-19 receiving standard 
therapy alone. We observed that the patients with severe COVID-19 receiving TMP/CTX 
in addition to ST had significantly better outcomes including reduced in-patient mortality 
(5% versus 32%), length of hospital stay (mean, 9 versus 22 days), and the need for 
ventilatory support (numbers, 3 versus 16) with improved clinical parameters within 48 
hours of starting treatment. This may be due to the anti-cytokine effects of TMP/CTX. 
Urgent clinical trials are recommended. 
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The Coronavirus Disease (COVID-19) pandemic carries an estimated mortality of 3.7-
4.3% compared with <1% for influenza and no proven treatment yet exists.1 Risk factors 
for more severe disease include male sex, obesity, ethnicity, hypertension and diabetes 
alongside prior cardiac or respiratory diseases.2 
A subgroup of patients with severe COVID-19 have unremitting fevers, blood 
cytopenia’s and 50% may develop pulmonary involvement associated with the over-
production of cytokines (soluble inflammatory immune mediators) generated by an 
increased immune response to the virus.3 This ‘cytokine storm’ involves interleukin 1, 2 
and 6, with interferon-γ and tumour necrosis factor-α. Together these cytokines lead to T-
lymphocyte, monocyte and neutrophil activation.4 Respiratory failure and acute 
respiratory distress syndrome (ARDS) are one of the most serious complications of 
pulmonary involvement with the mainstay of treatment being oxygen therapy. Some 
patients require non-invasive or invasive ventilatory support which is associated with 
higher mortality and possible multi-organ failure.5 
Although not universally recognized, the sulphonamide antibiotics dapsone (4, 4-
diaminodiphenolsulphone) and cotrimoxazole (a combination of trimethoprim- 
sulphamethoxazole) have effects upon the immune system which were first described for 
dapsone over 50 years ago. Both drugs share the same sulphonamide ring with similar 
antibacterial effects, with detailed studies of dapsone showing a dose-dependent 
reduction in the generation of tissue damaging ‘oxygen free radicals’ from neutrophils.6,7 
This reduction results from dapsone’s ability to block stimulation of the formyl peptide 
receptors (FPR), which are abundantly expressed on the surface of neutrophils and 
monocytes. Their activation drives the production of both intracellular and extracellular 
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oxygen free radical release leading to further inflammatory cytokine production.6,8 The 
blockade of FPR by dapsone therefore has marked anti-inflammatory effects.  Similar 
data exists for cotrimoxazole and trimethoprim.9,10 
From the medical literature there are scattered case reports describing clinical recovery 
from acute respiratory distress syndrome after the addition of cotrimoxazole, and here we 
report our experience with the use of trimethoprim and cotrimoxazole in the treatment of 
severe COVID-19.11,12 
All patients admitted with increasing fever, cough and breathlessness commenced 
standard therapy antibiotics of clarithromycin and benzyl penicillin for possible super 
infection secondary to COVID-19. These patients had been self-isolating for 7-10 days 
but had become increasing unwell leading to hospital admission. Their chest-X-ray’s or 
CT chest scans confirmed lung infiltrates in a pattern consistent with a radiological 
diagnosis of COVID-19. 
Since both cotrimoxazole and trimethoprim are licensed in the UK for the treatment of 
respiratory infections and pneumonia, we gave a 5-day course as best practice to patients 
demonstrating an acute hyper-inflammatory response (cytokine storm syndrome) with 
increasing fevers and oxygen requirements, who were considered to be at risk of further 
deterioration. These 22 patients commenced oral trimethoprim (TMP) 200mg 12hrly (18 
cases) or cotrimoxazole (CTX) 960mg 12hrly (4 cases); the latter containing 160mg of 
trimethoprim and 800mg sulphamethoxazole, in addition to standard antibiotic therapy.  
All patients fitted the WHO criteria for severe COVID-19.12 Historic data from record 
reviews of a further 22 patients with severe COVID-19 receiving standard therapy are 
also presented.  
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Baseline characteristics from anonymized record reviews are shown in table 1 for 
standard therapy patients and those treated with the addition of TMP or CTX to standard 
therapy. The groups were comparable for age, sex, ethnic group, diabetes, chronic lung 
disease, ischemic heart disease and chronic kidney disease. Hypertension was lower in 
the TMP/CTX added group at 14% compared with standard therapy alone at 50%. 
Baseline observations were similar for oxygen requirements (FiO2), respiratory rate, C-
reactive protein, body temperature and lung infiltrates (table 1).  All patients had 
neutrophil to lymphocyte ratios (NLR) >7.3. An NLR ratio >3.3 is documented to imply 
a poorer prognosis.13 
The SpO2/FiO2 ratio (peripheral oxygen saturations ÷ by inspired oxygen) correlates with 
acute lung injury, with ARDS being associated with a ratio below 315 in non-ventilated 
patients. For both patient groups this ratio was <250, confirming the clinical impression 
of ARDS.12,14 
At 48hrs (table 2) patients with added TMP or CTX showed a significant reduction in 
fevers, C-reactive protein, respiratory rate and oxygen requirements (FiO2). The 
SpO2/FiO2 ratio, which marks acute lung injury, had also improved to a mean of 320 that 
was consistent with reduced injury. The standard therapy patients showed no overall 
changes in any parameters (table 2).  
Figure 1 shows mean values with standard deviation and 95% confidence intervals from 
day 0 to day 5 for oxygen requirement (FiO2), SpO2/FiO2 ratio, body temperature and C-
reactive protein. This demonstrated continuing improvement for the added TMP/CTX 
patients.  
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21 out of 22 patients with added TMP or CTX were discharged well without oxygen after 
a mean stay of 9 days (table 2). There was 1 death due to ARDS (4.5%) during 
ventilation in the intensive care unit.  
Data from the patients receiving standard therapy alone, showed that 7 patients died 
(32%) from ARDS with a median time to death of 7 days (IQR range 5-20 days).    The 
mean length of hospital stay for surviving patients was 22 days; although 1 patient still 
remains in hospital. The standard therapy group required a total of 65 intensive care bed 
days versus 1 day for the TMP/CTX group.  
Figure 2 shows the Kaplan Meier plot for survival versus days from admission for the 
standard therapy (ST) and TMP/CTX with ST group.  
Data presented from our first 22 cases, suggests that the addition of oral TMP or CTX 
reduces acute lung injury in patients with severe COVID-19, thereby reducing the need 
for ventilatory support and improving outcomes. These drugs have no direct anti-viral 
effects but may offer protection against ARDS. The beneficial effects of TMP/CTX were 
apparent within hours of the first dose, likely reflecting their excellent absorption and 
lung penetration.   
Timely recognition of any clinical deterioration from the underlying cytokine storm 
syndrome is important. Delayed treatment, may reduce the ability of these drugs to act 
before blockade of the alveolar capillary bed by neutrophils occurs, with the risk of 
profound hypoxemia that may be difficult to reverse.15 
Published data shows that cotrimoxazole has anti-cytokine effects reducing interleukin-1, 
2, 6, 7, 8 and tumour necrosis factor-α production. Several of these cytokines are 
involved in the cytokine storm of COVID-19. This offers a possible explanation for the 
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observed clinical benefit by reducing neutrophil, monocyte and lymphocyte activation 
leading to a reduction in the risk of ARDS.16-20 
Trimethoprim or cotrimoxazole are inexpensive drugs licensed for use in respiratory 
infections with few serious side effects. They are generally available  
worldwide, and may have benefit in preventing acute lung injury in this pandemic. 
Cotrimoxazole may have advantages over trimethoprim due to the additional  
immune effects of sulphamethoxazole along with an intravenous preparation for use in 
deteriorating patients.  
Reducing ARDS and oxygen demand may be vital to saving lives in countries where 
healthcare may be easily overwhelmed. We recommend that these observations should be 
tested in clinical trials of TMP or CTX in the management of severe COVID-19.   
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Table 1: Baseline characteristics of patients with severe COVID-19 receiving 
trimethoprim (TMP)/cotrimoxazole (CTX) with standard therapy or standard 
therapy alone 
 TMP/CTX + 
standard therapy 
Standard therapy 
alone 
p-value* 
Subjects 22 22  
Age, mean (± SD)+ 59 (±15) 60 (±12) 0.760 
Male 59% 68% 0.531 
Ethnicity 
Asian 23% 14% 
0.615 
Afro-Caribbean 9% 9% 
Mixed 13% 5% 
Caucasian 55% 72% 
Comorbidities 
Hypertension 14% 50% 0.010 
Diabetes Mellitus 18% 27% 0.472 
Ischemic Heart Disease 9% 14% 0.635 
Chronic obstructive pulmonary disease 23% 9% 0.412 
Chronic kidney disease > 2 9% 23% 0.412 
Baseline observations: Day 0 
Clinical parameters                                                    mean ± SD mean ± SD  
Fraction of inspired oxygen (FiO2) 0.45 ± 0.17 0.44 ± 0.10 0.760 
Oxygen saturation/fraction of inspired 
oxygen (SpO2/FiO2) ratio 
244 ± 97 220 ± 49 0.690 
Respiratory rate (breaths/min) 24 ± 9 21 ± 5 0.952 
Body temperature (°C) 37.6 ± 0.8 37.8 ± 1 0.638 
C-Reactive Protein (mg/L) 120 ± 74 148 ± 74 0.307 
Neutrophil Lymphocyte ratio (NLR) 7.8 ± 9.8 7.4 ± 2.4 0.029 
% of subjects with infiltrates on the 
Chest X-Ray  91% 100% 0.488 
*Comparison between continuous variables and categorical variables was made by the Mann-Whitney U test and Chi Square 
test /Fishers exact test respectively. A p-value of <0.05 was considered statistically significant.  
+SD= Standard Deviation 
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Table 2: Primary outcomes and observations on day 0 and day 2 in patients with 
severe COVID-19 receiving trimethoprim (TMP)/cotrimoxazole (CTX) with 
standard therapy or standard therapy alone 
Primary Outcomes 
Outcome measures,  
number of cases (%) 
TMP/CTX + 
standard therapy 
Standard therapy 
alone 
p-value* 
Discharged 21 (95%) 14 (64%) 0.416 
Died  1(4.5%) 7 (32%) 0.046 
Ventilatory support 3 (14%) 16 (73%) <0.001 
Continuous positive airway pressure 2 (9%) 11(50%) 0.001 
Mechanical ventilation 1 (5%) 5 (23%) 0.185 
Length of stay in days, (mean ± SD+) 9 (± 4) 22 (± 13) <0.001 
Observations on Day 0 and Day 2: TMP/CTX + standard therapy (number of cases =22)                               
                                                                                mean ± SD+ mean ± SD+  
Clinical parameters Day 0 Day 2 p-value 
Fraction of inspired oxygen (FiO2) 0.45 ± 0.17 0.33 ± 0.13 0.001 
Oxygen saturation/fraction of inspired 
oxygen (SpO2/FiO2) ratio 
244 ± 97 320 ± 104 <0.001 
Respiratory rate (breaths/min) 24 ± 9 20 ± 2 0.035 
Body temperature (°C) 37.6 ± 0.8 36.7 ± 0.6 0.001 
C-Reactive Protein (mg/L) 120 ± 74 69 ± 42 0.002 
Observations on Day 0 and Day 2: Standard therapy alone (number of cases =22)                                         
                                                                                mean ± SD+ mean ± SD+  
Clinical parameters  Day 0 Day 2 p-value 
Fraction of inspired oxygen (FiO2) 0.44 ± 0.10 0.44 ± 0.14 0.864 
Oxygen saturation/fraction of inspired 
oxygen (SpO2/FiO2) ratio 
220 ± 49 241 ± 98 0.286 
Respiratory rate (breaths/min) 21 ± 5 21 ± 5 0.965 
Body temperature (°C) 37.8 ± 1 37.2 ± 0.9 0.097 
C-Reactive Protein (mg/L) 148 ± 74 186 ±104 0.040 
*Comparison between continuous and categorical variables was made by using Wilcoxon Signed Ranks test (for clinical 
parameters) / Mann-Whitney U test (for length of stay) and Chi Square test /Fishers exact test respectively. A p-value of 
<0.05 was considered statistically significant. +SD = standard deviation 
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Figure 1: Observations between Day 0 and Day 5 in patients with severe COVID-19 
receiving Trimethoprim (TMP)/Co-trimoxazole (CTX) with standard therapy (ST) 
or ST alone: A) Fraction of inspired oxygen (FiO2), B) SpO2 /FiO2 ratio, C) Body 
temperature and D) C-Reactive Protein 
 
Definition of abbreviations: SpO2 = peripheral capillary oxygen saturation; SD = standard deviation; 95% CI = 95% confidence 
interval; Data are presented as mean ± SD and 95% CI 
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Figure 2: Kaplan-Meier estimates of survival from date of admission comparing 
outcomes in patients with severe COVID-19 receiving Trimethoprim (TMP)/Co-
trimoxazole (CTX) with standard therapy (ST) or ST alone 
 
 
 
 
 
 
 
 
 
 
This preprint research paper has not been peer reviewed. Electronic copy available at: https://ssrn.com/abstract=3626443
References 
1. Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to 150 
COVID-19 based on analysis of 150 patients from Wuhan, China. Intensive Care Med 
2020;46 (5):846-848.  
2. Zhou F et al. Clinical course and risk factors for mortality of adult inpatients with 
COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020;395(10299)1054-
1062. 
3. Mehta P, McAuuley DF, Brown M, Sanchez E, Tattersall R, Manson J. COVID-19 
consider cytokine storm syndromes and Immunosuppression. Lancet 
2020;395(10229):1033-1034. 
4. Giavridis T, van der Stergen S, Eyquem J, Hamieh M, Piersigilli A, Sadelain M, 
Sadelain M. CAR T cell-induced cytokine release syndrome is mediated by macrophages 
and abated by IL-1 blockade. Nat Med 2018;24 (6):731-738. 
5. Wilcox SR. Management of respiratory failure due to covid-19. BMJ 2020;369;m1786. 
6. Suda T, Sukuki Y, Matsui T, Inoue O, Niide T, Yoshima H, Ochiai T. Dapsone 
suppresses human neutrophil superoxide production and elastase release in a 
calcium‐dependent manner.    
Br J Dermatol 2005;152 (5) 887-895. 
7. Booth SA, Moody CE, Dahl MV, Herron MJ, Nelson RD. Dapsone suppresses 
integrin-mediated neutrophil adherence function. J Invest Dermatol 1992;98(2):135-140. 
8. Niwa Y, Miyachi Y. Inhibitory effects of dapsone on enzymatic activities of membrane 
phospholipids in human blood cells. Arch Dermatol Res 1985;277(6):473-477. 
This preprint research paper has not been peer reviewed. Electronic copy available at: https://ssrn.com/abstract=3626443
9. Anderson R, Grabow G, Oosthuizen R, Theron A, Van Rensburg AJ. Effects of 
sulfamethoxazole and trimethoprim on human neutrophil and lymphocyte functions in 
vitro: In vivo effects of co-trimoxazole. Antimicrob Agents and Chemother. 
1980;17(3):322-326. 
10. Varney VA, Smith B, Quirke G, Parnell H, Rathneepan S,  Bansal AS, Nicolas A. 
P49 The effects  
of oral cotrimoxazole upon neutrophil and monocyte activation in patients with 
pulmonary fibrosis and healthy controls; does this relate to its action in idiopathic 
pulmonary fibrosis?  Thorax 2017:73(3):A109. 
11. Moniri A, Marjani M, Tabarsi P, Yadegarynia D, Nadji SA. Health Care Associated 
Middle East Respiratory Syndrome (MERS): A Case from Iran. Tanaffos. 
2015;14(4):262-267. 
12. World Health Organization  (2020). Clinical management of COVID-19: interim 
guidance, 27 May 2020. https://apps.who.int/iris/handle/10665/332196. License: CC BY-
NC-SA 3.0 IGO 
13. Yang A-P, Liu J, Tao W, Li H-M. The diagnostic and predictive role of NLR, d-NLR 
and PLR in COVID-19 patients. Int Immunopharmacol. 2020; 84:106504  
14. Adams JY, Rogers AJ, Schuler A, Marelich GP, Fresco JM, Taylor SL, Riedl AW, 
Baker JM, Escobar GJ, Liu VX. Association Between Peripheral Blood Oxygen 
Saturation (SpO 2)/Fraction of Inspired Oxygen (FiO 2) Ratio Time at Risk and Hospital 
Mortality in Mechanically Ventilated Patients. Perm J.2020;24(19);113-120. 
This preprint research paper has not been peer reviewed. Electronic copy available at: https://ssrn.com/abstract=3626443
15. Barnes BJ, Adrover JM, Baxter-stoltzfus A,  Borczuk A, Cools-Lartigue J. etal. 
Targeting Potential Drivers of COVID-19: Neutrophil Extracellular Traps. J. Exp. 
Med.2020;217(6):1-7. 
16.  Li L, Chen K, Xiang Y, Yoshimura T, Su S, Zhu J, Bian X-W, Wany JM. New 
Development in Studies of Formyl-Peptide Receptors: Critical Roles in Host Defense. J 
Leukoc Biol. 2016;99(3):425-435. 
17. Pichereau S, Moran JJ, Hayney MS, Shukla SK, Sakoulas G, Rose WE. 
Concentration-dependent effects of antimicrobials on Staphylococcus aureus toxin-
mediated cytokine production from peripheral blood mononuclear cells. J Antimicob 
Chemother. 2012;67(1):123-129. 
18. Vickers IE, Smikle MF. The Immunomodulatory Effect of Antibiotics on the 
Secretion of Tumour Necrosis Factor Alpha by Peripheral Blood Mononuclear Cells in 
Response to Stenotrophomonas Maltophilia Stimulation. West Indian Med. J. 
2006;55(3):138-141. 
19. Richter J, Ng-Sikorski J, Olsson I, Andersson T. Tumor necrosis factor-induced 
degranulation in adherent human neutrophils is dependent on CD11b/CD18-integrin-
triggered oscillations of cytosolic free Ca2+. Proc Natl Acad Sci U S A. 
1990;87(23):9472‐9476.   
20.Bourke CD et al. Cotrimoxazole Reduces Systemic Inflammation in HIV Infection by 
Altering the Gut Microbiome and Immune Activation.   Sci Transl Med.2019; 
11(486):eaav0537. 
This preprint research paper has not been peer reviewed. Electronic copy available at: https://ssrn.com/abstract=3626443
